Categories: BioTechFutureMarketMedTechOwnProductProductionTechnology
Vanarix develops cartilage regeneration, the first autologous hyaline cartilage microtissues of high quality, designed for everyone whatever your age. We offer a new technology to treat cartilage lesions. We have developed and recently patented a method for the production of Cartibeads
Investors 1
Mentions in press and media 6
| Date | Title | Description |
| 06.01.2025 | Vanarix obtains Orphan Disease Designation from the FDA |
Founded in 2018 by Vannary Tieng and her co-founders Eric Gerstel and Alessandra de Picciotto, Vanarix is making significant strides in regenerative medicine with a focus on articular cartilage regeneration. The company has developed a med... |
| 10.12.2024 | Swiss medtechs maintain momentum |
Dedicated to developing solutions that simplify and streamline the generation of "big RNA data, Alithea genomics develops BRB-seq technologies and kits enable researchers to discover novel biomarkers and essential data needed to devel... |
| 17.07.2024 | CHF 4M and new clinical trials for Vanarix |
Co-founded by Vannary Tieng (CEO) and Alessandra de Picciotto (Chairman) in 2018, Vanarix is a Swiss clinical stage startup specializing in regenerative medicine, focusing on articular cartilage regeneration. The company raised this year C... |
| 05.12.2022 | First successful transplantation for Vanarix | |
| 21.07.2022 | Ten Biotech startups brace for Boston | |
| - | Vanarix | “Vanarix develops cartilage regeneration, the first autologous hyaline cartilage microtissues of high quality, designed for everyone whatever your age. We offer a new technology to treat cartilage lesions. We have developed and recently pat... |
Reviews 0
